Takeda acquires Millennium

When I profiled Millennium Pharmaceuticals' chief scientific officer, Joe Bolen, in last month's issue of __The Scientist,__ he described some amusing airport foibles that had taken place during a linkurl:recent trip to Japan.;http://www.the-scientist.com/article/display/54340/ Now the whole company is going to Japan - at least on paper. Today, Millennium Pharmaceuticals, one of the first genomics companies in the US, was linkurl:acquired;http://investor.millennium.com/phoenix.zhtml?c=80159&p=ir

By | April 10, 2008

When I profiled Millennium Pharmaceuticals' chief scientific officer, Joe Bolen, in last month's issue of __The Scientist,__ he described some amusing airport foibles that had taken place during a linkurl:recent trip to Japan.;http://www.the-scientist.com/article/display/54340/ Now the whole company is going to Japan - at least on paper. Today, Millennium Pharmaceuticals, one of the first genomics companies in the US, was linkurl:acquired;http://investor.millennium.com/phoenix.zhtml?c=80159&p=irol-newsArticle&ID=1127852&highlight= by Takeda Pharmaceuticals, Japan's largest pharma company, for a whopping $8.8 billion dollars. Although Millennium will become a wholly owned subsidiary, the company will continue its operations in Cambridge Massachusetts.

Popular Now

  1. Decoding the Tripping Brain
  2. Tattoo Ink Nanoparticles Persist in Lymph Nodes
    The Nutshell Tattoo Ink Nanoparticles Persist in Lymph Nodes

    Analysis of the bodies of deceased individuals can’t determine what effect these tattoo remnants have on lymph function, but researchers suggest dirty needles aren’t the only risk of the age-old practice.

  3. Do Microbes Trigger Alzheimer’s Disease?
  4. Metabolomics Data Under Scrutiny
    Daily News Metabolomics Data Under Scrutiny

    Out of 25,000 features originally detected by metabolic profiling of E. coli, fewer than 1,000 represent unique metabolites, a study finds.

AAAS